Dr Shelley Chu

KANDO id: 12783

Bio

Dr. Shelley Chu joined Frazier Healthcare in 2005 as a Vice President and became a Principal in 2007. Dr. Chu is a member of Frazier Healthcare’s biopharma investment team. She co-led the company formation and founding investment in Kalidex, with serial entrepreneurs from Calixa and Cerexa, and is a Board Director. She played significant roles in the firm’s initial investments in Cadence (CADX) and Cerexa (acquired by Forest), both companies which now have approved NDAs, as well as Marcadia (acquired by Roche) and Intradigm (acquired by Silence). She is actively involved with Achaogen, Anaptys, Kalidex and Tobira. Dr. Chu has over 15 years of scientific, clinical and business experience. Prior to Frazier Healthcare, she worked at Flagship Ventures, where she focused on company building in biotherapeutics and platform companies. Dr. Chu was previously with McKinsey & Co. where she advised biotechnology and pharmaceutical companies on critical strategic and R&D issues. Dr. Chu received her M.D. and Ph.D. in Biochemistry & Biophysics from the University of California, San Francisco, where she was elected to Alpha Omega Alpha and co-founded the UCSF Mini Medical School. She is first author of multiple scientific and clinical publications in Science and other prominent journals. Dr. Chu also holds a B.A. summa cum laude in Molecular Biology from Princeton University.

Career


Frazier Healthcare Ventures

Investment firm providing growth and venture capital to healthcare companies.
N/A (past)
Email: [email protected]

Education